Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study.

<h4>Objective</h4>The aim of the study was to assess inflammatory markers and clinical outcomes in adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a combination of standard-of-care (SOC) and targeted immunosuppressive therapy including anti-IL-17A (net...

Full description

Bibliographic Details
Main Authors: Ekaterina A Bryushkova, Valeria D Skatova, Zinaida Y Mutovina, Alena I Zagrebneva, Daria S Fomina, Tatyana S Kruglova, Anna A Akopyan, Irina D Strazhesko, Sergey A Lukyanov, Olga N Tkacheva, Maryana A Lysenko, Dmitry M Chudakov
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0273340

Internet

https://doi.org/10.1371/journal.pone.0273340

Similar Items